Seattle Genetics Inc News Releases http://investor.seagen.com/ Seattle Genetics Inc News Releases en Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML) http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-announces-multiple-adcetrisr-brentuximab-0 -Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 12, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS ® (brentuximab vedotin) clinical development program at the 24 th Annual Congress of Wed, 12 Jun 2019 08:00:00 -0400 Seattle Genetics Inc News Releases 17951 Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-antibody-drug-conjugate-technology-utilized -Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 10, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration ( FDA ) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug Mon, 10 Jun 2019 12:51:00 -0400 Seattle Genetics Inc News Releases 17946 Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-announces-additional-analyses-echelon-1-and Three-Year Update of ECHELON-1 Trial Continues to Demonstrate Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Hodgkin Lymphoma Analyses Describe ADCETRIS Activity in T-Cell and B-Cell Non-Hodgkin Lymphomas Across All Levels of CD30 Mon, 03 Jun 2019 08:00:00 -0400 Seattle Genetics Inc News Releases 17931 Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-and-astellas-announce-antibody-drug-conjugate - First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor- -Data Featured in Official Press Program and Presented in Late-Breaking Oral Session Today at 2019 ASCO Mon, 03 Jun 2019 07:30:00 -0400 Seattle Genetics Inc News Releases 17921 Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-appoints-robin-taylor-phd-chief-commercial BOTHELL, Wash. --(BUSINESS WIRE)--May 21, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Robin G. Taylor , M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of Tue, 21 May 2019 08:00:00 -0400 Seattle Genetics Inc News Releases 17861 Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-announces-presentations-new-clinical-data First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3 rd BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from six of its Wed, 15 May 2019 17:10:00 -0400 Seattle Genetics Inc News Releases 17856 Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-present-rbc-capital-markets-2019-global BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time . The presentation will be webcast live and available Wed, 15 May 2019 08:00:00 -0400 Seattle Genetics Inc News Releases 17851 Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-announces-progress-expanding-adcetrisr -Health Canada Approves ADCETRIS in Combination with AVD Chemotherapy for the Treatment of Previously Untreated Hodgkin Lymphoma Based on Positive Phase 3 ECHELON-1 Clinical Trial Results- -Supplemental New Drug Submission Completed for ADCETRIS in Combination with CHP Chemotherapy in Frontline Fri, 03 May 2019 12:09:00 -0400 Seattle Genetics Inc News Releases 17826 Seattle Genetics Reports First Quarter 2019 Financial Results http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-reports-first-quarter-2019-financial-results -ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42 Percent Over the First Quarter of 2018- -Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Support Planned Thu, 25 Apr 2019 16:02:00 -0400 Seattle Genetics Inc News Releases 17791 Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019 http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-host-conference-call-and-webcast-discussion-55 BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 4, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference Thu, 04 Apr 2019 08:00:00 -0400 Seattle Genetics Inc News Releases 17751